Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

NCT03875859 PHASE2 TERMINATED Results posted

The primary purpose of this study is to determine if 8 weeks of topical remetinostat applied three times daily will suppress Squamous Cell Carcinoma.

Details

Lead sponsor	Kavita Sarin
Phase	PHASE2
Status	TERMINATED
Enrolment	4
Start date	Thu Dec 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Jan 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Squamous Cell Carcinoma

Interventions

• Remetinostat

Countries

United States